» Articles » PMID: 28805342

Deletion of the Activating NK Cell Receptor NKG2D Accelerates Rejection of Cardiac Allografts

Overview
Journal Am J Transplant
Publisher Elsevier
Specialty General Surgery
Date 2017 Aug 15
PMID 28805342
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

It has already been shown that neutralization of the activating NK cell receptor NKG2D in combination with co-stimulation blockade prolongs graft survival of vascularized transplants. In order to clarify the underlying cellular mechanisms, we transplanted complete MHC-disparate BALB/c-derived cardiac grafts into C57BL/6 wildtypes or mice deficient for NKG2D (Klrk1 ). Although median survival was 8 days for both recipient groups, we detected already at day 5 posttransplantation significantly greater intragraft frequencies of NKp46 NK cells in Klrk1 recipients than in wildtypes. This was followed by a significantly greater infiltration of CD4 , but a lesser infiltration of CD8 T cell frequencies. Contrary to published observations, co-stimulation blockade with CTLA4-Ig resulted in a significant acceleration of cardiac rejection by Klrk1 recipients, and this result was confirmed by applying a neutralizing antibody against NKG2D to wildtypes. In both experimental setups, grafts derived from Klrk1 recipients were characterized by significantly higher levels of interferon-γ mRNA, and both CD4 and CD8 T cells displayed a greater capacity for degranulation and interferon-γ production. In summary, our results clearly illustrate that NKG2D expression in the recipient is important for cardiac allograft survival, thus supporting the hypothesis that impairment of NK cells prevents the establishment of graft acceptance.

Citing Articles

Innate immune cellular therapeutics in transplantation.

Ott L, Cuenca A Front Transplant. 2023; 2.

PMID: 37994308 PMC: 10664839. DOI: 10.3389/frtra.2023.1067512.


Interferon-β acts directly on T cells to prolong allograft survival by enhancing regulatory T cell induction through Foxp3 acetylation.

Fueyo-Gonzalez F, McGinty M, Ningoo M, Anderson L, Cantarelli C, Angeletti A Immunity. 2022; 55(3):459-474.e7.

PMID: 35148827 PMC: 8917088. DOI: 10.1016/j.immuni.2022.01.011.


NKG2D Natural Killer Cell Receptor-A Short Description and Potential Clinical Applications.

Siemaszko J, Marzec-Przyszlak A, Bogunia-Kubik K Cells. 2021; 10(6).

PMID: 34200375 PMC: 8229527. DOI: 10.3390/cells10061420.


The natural killer cell activating receptor, NKG2D, is critical to antibody-dependent chronic rejection in heart transplantation.

Lin C, Gill R, Mehrad B Am J Transplant. 2021; 21(11):3550-3560.

PMID: 34014614 PMC: 9036609. DOI: 10.1111/ajt.16690.


Artemisinin Attenuates Transplant Rejection by Inhibiting Multiple Lymphocytes and Prolongs Cardiac Allograft Survival.

Yang Z, Han F, Liao T, Zheng H, Luo Z, Ma M Front Immunol. 2021; 12:634368.

PMID: 33717174 PMC: 7943449. DOI: 10.3389/fimmu.2021.634368.


References
1.
Chen H, Xia J, Zhang L, Jin X, Yang M, Li J . NKG2D blockade attenuated cardiac allograft vasculopathy in a mouse model of cardiac transplantation. Clin Exp Immunol. 2013; 173(3):544-52. PMC: 3949642. DOI: 10.1111/cei.12128. View

2.
Lin C, Plenter R, Coulombe M, Gill R . Interferon Gamma and Contact-dependent Cytotoxicity Are Each Rate Limiting for Natural Killer Cell-Mediated Antibody-dependent Chronic Rejection. Am J Transplant. 2016; 16(11):3121-3130. PMC: 5083186. DOI: 10.1111/ajt.13865. View

3.
Kunert K, Seiler M, Mashreghi M, Klippert K, Schonemann C, Neumann K . KIR/HLA ligand incompatibility in kidney transplantation. Transplantation. 2007; 84(11):1527-33. DOI: 10.1097/01.tp.0000290681.41859.41. View

4.
Zafirova B, Mandaric S, Antulov R, Krmpotic A, Jonsson H, Yokoyama W . Altered NK cell development and enhanced NK cell-mediated resistance to mouse cytomegalovirus in NKG2D-deficient mice. Immunity. 2009; 31(2):270-82. PMC: 2782462. DOI: 10.1016/j.immuni.2009.06.017. View

5.
Jamieson A, Diefenbach A, McMahon C, Xiong N, Carlyle J, Raulet D . The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity. 2002; 17(1):19-29. DOI: 10.1016/s1074-7613(02)00333-3. View